Tag
This review synthesizes evidence on colchicine’s efficacy in secondary stroke prevention, emphasizing the impact of concomitant atherosclerosis on outcomes from the CONVINCE trial and meta-analyses.
This pilot randomized trial demonstrates the feasibility of using low-dose colchicine after acute intracerebral hemorrhage to prevent vascular events, highlighting considerations for future larger studies regarding recruitment, adherence, a
A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing t
A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su
A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.
An updated meta-analysis evaluates the effects of 0.5 mg colchicine on clinical outcomes after acute myocardial infarction, showing reduced hospital readmission but increased diarrhea risk without significant impact on major cardiovascular
